SBI Okasan Asset Management Co.Ltd. purchased a new position in shares of Abbott Laboratories (NYSE:ABT – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 9,190 shares of the healthcare product maker’s stock, valued at approximately $1,145,000.
Several other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after purchasing an additional 2,402,408 shares in the last quarter. Capital International Investors raised its holdings in Abbott Laboratories by 2.5% during the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock worth $8,251,974,000 after purchasing an additional 1,478,076 shares in the last quarter. Invesco Ltd. raised its holdings in Abbott Laboratories by 51.0% during the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after purchasing an additional 4,713,135 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Abbott Laboratories by 3.8% during the third quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker’s stock worth $1,804,050,000 after purchasing an additional 499,351 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in Abbott Laboratories by 7.2% during the third quarter. Legal & General Group Plc now owns 12,900,318 shares of the healthcare product maker’s stock worth $1,727,869,000 after purchasing an additional 864,531 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.
Trending Headlines about Abbott Laboratories
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: Abbott secured CE Mark approval in Europe for Libre Duo, the world’s first dual glucose-ketone sensing technology for diabetes care, which could broaden its addressable market and strengthen its diabetes device franchise. Article Title
- Positive Sentiment: The American Cancer Society reaffirmed Abbott’s noninvasive colorectal cancer screening products, Cologuard and Cologuard Plus, as preferred options for average-risk adults, supporting demand for the company’s screening portfolio. Article Title
- Positive Sentiment: Abbott also won FDA and EU clearance for its AI-powered Ultreon 3.0 software, which helps guide artery stent placement and could support growth in its cardiovascular business. Article Title
- Neutral Sentiment: Analyst-focused articles reiterated that Wall Street remains broadly bullish on Abbott, and Goldman Sachs maintained a Buy rating even after trimming its price target to $113 from $121. Article Title
- Neutral Sentiment: Commentary on Abbott’s diagnostics unit pointed to a mixed quarter, with Core Lab growth offset by China weakness and softer respiratory testing demand, suggesting uneven near-term performance in the segment. Article Title
- Negative Sentiment: Some market coverage noted that Abbott’s shares fell in a recent session despite a broader market uptick, reflecting lingering pressure even as fundamental news flow turns more favorable. Article Title
Abbott Laboratories Stock Up 0.6%
Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the business earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages have weighed in on ABT. Bank of America lowered their target price on shares of Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Wells Fargo & Company lowered their target price on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. The Goldman Sachs Group lowered their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research report on Wednesday. Royal Bank Of Canada lowered their target price on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Finally, Raymond James Financial lowered their target price on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $119.09.
Read Our Latest Analysis on ABT
Insiders Place Their Bets
In other news, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the sale, the vice president directly owned 24,628 shares in the company, valued at $2,846,504.24. This represents a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president owned 146,377 shares in the company, valued at $16,918,253.66. This represents a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.
Abbott Laboratories Profile
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Read More
- Five stocks we like better than Abbott Laboratories
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
